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ABSTRACT 
Objective: Docetaxel (DTX), a potent anticancer drug, is suffering from non-specificity and drug resistance as major limitations. In this 
investigation, we developed Hyaluronic acid (HA)-Docetaxel conjugate (HA-DTX) loaded nanoliposomes to target cancer cells via passive and active 
targeting approaches.  
Methods: HA-DTX was synthesized and characterized by UV-Visible spectrophotometry, FT-IR spectroscopy, 1H NMR spectroscopy, Differential 
scanning calorimetry and X-ray diffraction and then loaded into nanoliposomes (L-NLs) by thin-film hydration method. L-NLs were characterized 
physicochemically and evaluated for anticancer efficacy by in vitro cytotoxicity study in glioma cells (C6 glial cells); cellular uptake and apoptotic 
effect were investigated by fluorescence microscopy.  
Results: HA-DTX was successfully synthesized; L-NLs had an average size of 123.0±16.53 nm, polydispersity index of 0.246±0.01 and zeta potential 
of -44.4±6.79 mV. Also, L-NLs exhibited 90.54%±4.22 of drug loading efficiency and 2.68%±0.12 of drug loading, releasing about 57.72%±1.17 at 
pH 5.2 and only 14.14%±1.32 at pH 7.4 after 48 h. No significant change in stability was observed after storage at 5 °C±3 °C as well as at 25 °C±2 
°C/60% RH±5% RH for 6 mo. The cytotoxicity effect of L-NLs was higher by 10% then that of marketed formulation at 10 µg/ml docetaxel 
concentration. Fluorescence microscopic investigation showed that more cellular uptake and apoptotic effect were observed in L-NLs treated C6 
glial cells than in those treated with the marketed formulation.  
Conclusion: HA-DTX loaded nanoliposomes enabled docetaxel to target C6 glial cells with better efficacy and might be effective to treat glioma. 
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INTRODUCTION 
Cancer is continued to be the second leading cause of death globally 
[1, 2]. Among the many types malignant glioma is the most 
aggressive, lethal, and prevalent brain cancer. The term “glioma” 
encompasses all tumors that arise from glial cells [3-5]. Gliomas 
account for approximately 30% of all CNS tumors [6] and more than 
50% of all brain tumors in adults [7]. The current standard clinical 
treatments for malignant glioma include radiation therapy, 
chemotherapy with antineoplastic agents, and resection of the 
accessible tumor. However, these treatment options bring about 
toxic effects to healthy tissue or damage the brain tissue, suffer from 
intrinsic resistance pathways, and require regular dose regimens. 
Therefore, there is a strong need to develop a novel approach that 
can overcome these limitations and alleviate the burden of 
malignant glioma [3, 4, 8]. One method is based on the development 
of lipophilic and nanosize drug carriers, which enable 
chemotherapeutic agents to permeate through the blood-brain 
barrier (BBB) and make them insusceptible to efflux pump. In this 
regard, liposomes are represented as a promising system to get to 
the brain and target tumor cells [3]. Moreover, their biocompatibility 
and ability of sustained drug release significantly reduce the dose-
related side effects [4, 9]. Thus, the appropriate size of the liposomal 
formulation is a vital aspect in order to develop efficient 
therapeutics against glioma. In general, a nanosize (<200 nm) drug 
carrier can make use of the advantages of leaky vasculature 
associated with brain cancer for extravasation of chemotherapeutic 
agents into the tumor easily via EPR mechanism [10, 11]. 
Docetaxel (DTX), a semisynthetic analog of paclitaxel, is currently 
widely used for the treatment of breast, ovary, uterus body, prostate, 
gastric, esophageal, non-small cell lung, head and neck cancers [12-
15]. DTX is approximately two times as potent as paclitaxel and at 
least five times more potent against paclitaxel-resistant cells. But, 
multi-drug resistance severely affects its anticancer efficacy due to 
the efflux effect by transporters overexpressed in cancer cells [16]. 
In addition, its use in the treatment of glioma is greatly limited 
because of its poor BBB permeation ability. As a result, most of the 
available marketed formulations of DTX are not able to cross the 
BBB efficiently and also accompanied with various side effects, 
including allergic reactions with some cases of fatal anaphylaxis due 
to ploysorbate 80 (Tween 80) used in the formulation, lowing of 
white blood cells count, nephrotoxicity, neurotoxicity, cumulative 
fluid retention etc, [9, 17, 18].  
Polymer-anticancer drug conjugate system is one of the techniques 
used to modify the characteristics of free anticancer drugs and 
improve their therapeutic effects [19-21]. Among others, hyaluronic 
acid (HA)-anticancer drug conjugates could help to achieve targeting 
of anticancer agents to tumor cells [22]. HA is a natural ligand for 
CD44, receptors over-expressed on the surface of many cancer cells 
[23] and has been shown in more in glioma cells compared to 
healthy astrocytes [8]. HA also possesses other favorable properties 
such as hydrophilicity, biocompatibility, biodegradability, and non-
immunogenicity. Conjugation involves covalently linking HA to 
anticancer drugs via linkers such as hydrazide, succinate, amide and 
ester linkages, which can readily be cleaved after reaching the target 
site [22, 24, 25]. Thus, HA-Docetaxel conjugate can result in targeted 
delivery to cancer cells with sustained release profile and improved 
antitumor activity.  
Though DTX loaded liposomes [26, 27] have been reported, no 
investigation has been done on nanoliposomes loaded with 
Hyaluronic acid-Docetaxel conjugate (HA-DTX), which possess the 
advantages of dual targeting mechanisms viz: passive targeting via 
EPR effect and active targeting through CD44-mediated endocytosis. 
Based on the above information, the authors hypothesized that HA-
DTX loaded nanoliposomes would be a potential carrier to deliver 
DTX to glial tumor cells via passive and active targeting. Thus, the 
aim of the present study was to develop HA-DTX loaded 
nanoliposomes for targeting tumor cells by the simultaneous 
mechanism of passive targeting through EPR effect in which 
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nanosize vesicles permeate through tumor vasculature, and active 
targeting by the HA binding specifically to CD44 receptor, which is 
over-expressed in glial tumor cells, and thus might be an effective 
therapy against glioma. 
MATERIALS AND METHODS 
Materials 
Docetaxel trihydrate (Batch no. DT/F/18001) was provided by 
SURAJLOK Chemicals Pvt. LTD. (Mumbai, India), Docetaxel injection 
(Daxotel) (Batch no. 888NJ001) was purchased (Invoice no. M-
0020482) from New Sanjibani Medical Store (Dibrugarh, India). 
Hyaluronic acid sodium salt (40-50 KDa), 1-Ethyl-3-[3-
(dimethylamino)-propyl]-carbodiimide (EDC) hydrochloride, N-
Hydroxy succinimide (NHS), Triethylamine (TEA), Soya lecithin (SL), 
Cholesterol (CHL), Ham’s F12 medium with 2 mmol L-glutamine and 
1.5 g/l Sodium bicarbonate, Fetal Bovine Serum (FBS), Trypsin-
EDTA, Antibiotic Solution 100X liquid (10,000 U/l penicillin and 10 
mg/l streptomycin), EZcountTM MTT Cell Assay Kit [comprises 3-
(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
reagent (powder), Cell-based assay buffer, and solubilization 
solution], Sterile phosphate-buffered saline (PBS) pH 7.4, Six-and 
twelve-well plates, 96-well flat bottomed microassay plates, cell 
culture flasks and petri dishes, coverslips, glass slides and dialysis 
membrane were all procured from HiMedia Laboratories Pvt. Ltd. 
(Mumbai, India). CellEventTM Caspase-3/7 Green Reagent was 
purchased from Thermo Fisher Scientific Inc. (Invitrogen, India). C6 
glial cell line was purchased from the National Centre for Cell 
Science (NCCS) (Pune, India). All other reagents used were of 
analytical grade.  
Methods 
Synthesis of the Hyaluronic Acid-Docetaxel conjugate (HA-DTX) 
In the synthesis of HA-DTX, a previously developed method [28] with 
minor modifications was used for the desalting of HA sodium salt. In 
brief, HA sodium salt (40-50 kDa) was desalted by dissolving the 
amount required in de-ionized water and the solution was dialyzed 
using a pretreated dialysis tube (MWCO 14 kDa) against de-ionized 
water for 24 h. The desalted HA was lyophilized using lyophilizer 
(SCANVAC Coolsafe 55-4, Labogen, Denmark) for 24 h at-51 °C and 
stored at 2-8 °C until it was used. Similarly, a method used elsewhere 
[29] was adopted with some modifications for the conjugation of HA to 
DTX. In brief, the desalted HA (equivalent to 0.15 mmol of carboxylic 
group) was dissolved in 12 ml of de-ionized water. Then, both EDC 
(0.3 mmol) and NHS (0.3 mmol) were dissolved in 2 ml of DMSO and 
slowly added to the HA solution. The resulting mixture was stirred for 
1 h at room temperature to activate the carboxylic group of HA. 
Subsequently, DTX (0.3 mmol) dissolved in 10 ml of anhydrous DMSO 
and TEA (0.3 mmol) were added to the activated HA solution. The 
reaction mixture was then allowed to react at room temperature with 
mild stirring for 24 h. After 24 h, the resulting product was dialyzed 
successively using pretreated dialysis tubing (MWCO 14 kDa) against 
an excess of acetone-water solution (50:50, v/v), ethanol solution 
(25% v/v) and then de-ionized water in order to purify the product 
from reactants. Then, the obtained solution was lyophilized (SCANVAC 
Coolsafe 55-4, Labogen, Denmark) for 48 h at -51 °C and stored at -20 
°C for further use.  
Characterization of Hyaluronic Acid-Docetaxel conjugate  
UV-visible spectrophotometry 
The UV absorption maxima (λ Max) of both DTX and HA-DTX and 
concentration of DTX in the conjugate were determined by using UV-
Visible Spectrophotometer (UV-1800, SHIMADZU, JAPAN). The 
percent of DTX conjugation and the percent of the DTX loading 
amount was calculated using the following formulas. 
Percent of DTX conjugation (% w/w)
=
Amount of DTX in conjugate 
Amount of DTX in feed
ₓ 100 
Drug loading amount (% w/w)
=
Amount of DTX in conjugate obtained
Total weight of the conjugate obtained
 ₓ 100 
Fourier-transform infrared (FT-IR) spectroscopy 
The FT-IR spectra of HA-DTX conjugate, pure HA and pure DTX were 
obtained using FT-IR spectrophotometer (BRUKER ALPHA, 
Germany). The scanning range was 400 to 4000 cm-1 and the 
resolution used was 2 cm-1.  
Proton-nuclear magnetic resonance (1H NMR) spectroscopy 
The 1H NMR spectra of HA-DTX conjugate, pure HA and pure DTX 
were obtained by using Nuclear Magnetic Resonance Spectrometer 
(AVANCE III 500 MHz FT-NMR Spectrometer, BRUKER, 
Switzerland). Two different solvents, namely deuterated dimethyl 
sulfoxide (DMSO-d6) and deuterium oxide (D2O) were used to obtain 
characteristic proton peaks of DTX and HA, respectively.  
Differential scanning calorimetry 
Differential Scanning Calorimetry (DSC) analysis was performed to 
access the crystallinity and the thermal behavior of the Hyaluronic 
acid-Docetaxel conjugate using a Differential Scanning Calorimeter 
(Jade DSC, Perkin Elmer, USA). A weighted sample of about 6 mg was 
sealed hermetically in the standard aluminum pans. The sample was 
subjected to a heating program in the DSC instrument from 30 °C to 
300 °C at a heating rate of 10 °C/min under nitrogen purging at a 
flow rate of 20 ml/min. 
X-Ray diffraction (XRD) study  
The XRD diffractograms of DTX and HA-DTX were obtained by using 
X-Ray Diffractometer (Ultima IV, Rigaku, Japan). The instrument was 
operated at a voltage of 40 kV and 25 mA. The scanned angle was set 
at 2Ɵ from 3° to 65° and scanned at a rate of 1°/min. 
Preparation of HA-DTX loaded nanoliposomes  
HA-DTX loaded nanoliposomes (L-NLs) were prepared by the lipid 
film hydration method [9]. Briefly, required quantities of 
cholesterol: soya lecithin (in 1:2 w/w ratio) containing 1% w/w 
butylated hydroxytoluene (BHT) were taken into a 250 ml round 
bottom flask and dissolved in 10 ml of chloroform. The mixture was 
then mixed by gentle shaking at 130 rpm using a rotary vacuum 
evaporator (IKA RV 8, Germany) and the solvent was evaporated at 
40 °C while rotating the flask in a water bath. Further, it was kept 
overnight in a vacuum desiccator to completely remove the solvent 
residue. The thin film obtained was hydrated for 60 min in PBS, pH 
7.4, containing HA-DTX in the amount of 1:10 w/w of that of soya 
lecithin using the rotary vacuum evaporator rotating the flask at 160 
rpm in the water bath heated at 60 °C. The suspension then was 
stirred at 500 rpm using magnetic stirrer for 5 min and then 
sonicated by a bath sonicator (UCB 30, SPECTRALAB Instruments 
Pvt. Ltd, India) at about 30±3 KHz for 30 min. After preserving the 
suspension for overnight at 4 °C it was centrifuged at 4 °C and at 
16000 rpm for 60 min using a centrifuge (CPR-24 PLUS, REMI, 
INDIA) to get rid of the untrapped HA-DTX conjugate and to obtain 
the mass of nanoliposomes. The mass of nanoliposomes was 
collected in a petri dish and lyophilized using lyophilizer (SCANVAC 
Coolsafe 55-4, Labogen, Denmark) for 24 h at -51 °C to get dry 
nanoliposomes (L-NLs). Blank nanoliposomes (B-NLs) 
(nanoliposomes without HA-DTX) were prepared in the same way 
except that HA-DTX was not added into the hydration medium. 
Characterization of HA-DTX loaded nanoliposomes 
Percentage yield  
The yield of dried nanoliposomes was determined by weighing 
immediately after lyophilization and percentage yield was then 
determined by the following formula:  
Percentage yield =
Weight of dry nanoliposomes obtained 
Total weight of formulation components 
 ₓ 100 
Particle size, Polydispersity index (PDI) and Zeta potential 
To evaluate particle size, polydispersity index (PDI) and zeta 
potential, the lyophilized nanoliposomes (L-NLs) were reconstituted 
in double distilled water and diluted until the appropriate 
concentration of particles was achieved. The size and PDI of the L-
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NLs were determined by Zetasizer (ZEN3690, MALVERN, UK) based 
on dynamic light scattering technique. Zeta potential was also 
measured by the same instrument using the principle of 
electrophoretic mobility in an electric field. All measurements were 
performed in triplicate at 25 °C.  
Percentage of drug loading and loading efficiency 
A 5 mg sample of the L-NLs was lysed by sonication followed by 
vortex (RQ-122, REMI MOTOR, INDIA) in PBS pH 7.4 containing 
0.5% w/v SLS, and the dissolved sample was centrifuged (Heraeus 
Fresco 17, Thermo Fisher Scientific, Germany) at 13000 rpm for 10 
min. The supernatant was carefully taken and its absorbance was 
measured at 231.0 nm by using an Ultraviolet-Visible 
spectrophotometer (UV-1800, Shimadzu, Japan). The same 
procedure was repeated for B-NLs to get absorbance to nullify the 
effect of excipients on DTX absorbance readings by subtracting the 
readings of the absorbance of B-NLs from those of L-NLs. The 
percentage of drug loading and loading efficiency was calculated 
using the following equations [30]. 
Percentage of drug loading (%) =
Amount of DTX in L– NLs 
Amount of L– NLs 
ₓ 100 




Surface morphology study by scanning electron microscopy (SEM) 
The surface morphology of L-NLs was analyzed by a scanning 
electron microscope (JSM-IT300; JEOL, Tokyo, Japan). Lyophilized 
samples were spread on a carbon tape over a stub, platinum-coated 
and examined using SEM at an accelerating voltage of 20 kV.  
Fourier-transform infrared (FT-IR) spectroscopy 
The pure excipients (i.e., SL and CHL), HA-DTX, physical mixture (SL, 
CHL and HA-DTX) of the formulation components and the 
lyophilized nanoliposomes (L-NLs) were separately scanned from 
400 to 4000 cm-1 with a resolution of 2 cm-1 using FT-IR 
spectrophotometer (BRUKER ALPHA) to investigate the HA-DTX 
conjugate interaction with the excipients [30].  
In vitro drug release study 
The in vitro release behavior of DTX from L-NLs was studied using 
dialysis bag method [30, 31] in release media of two different pH, 
physiological pH (pH 7.4) and mildly acidic pH (pH 5.2) and also 
compared to the marketed formulation (Daxotel). Since the passage 
of a drug across the dialysis membrane is a passive process [32], the 
rate of permeation of DTX through the dialysis membrane was 
assumed to be higher than the rate of release of DTX from the 
nanoliposomes in the release medium. Briefly, 50 ml of PBS, pH 7.4, 
or pH 5.2 containing 0.5% w/v SLS was taken as drug release media 
in a borosilicate glass beaker of 100 ml capacity and warmed up to 
and kept at 37±0.5 °C. Accurately weighed 5 mg of L-NLs and an 
equivalent amount of marketed formulation (Daxotel) was separately 
reconstituted with 1 ml release media and transferred into a 
pretreated dialysis bag (MWCO 14 kDa) tied at one end. The bag 
containing the marketed formulation or L-NLs was tied at both ends 
and suspended in the release media in the glass beaker. The beaker 
was placed on a magnetic stirrer and the content of the formulations 
was magnetically stirred at 300 rpm, and the temperature was 
maintained using a thermostatically controlled heater of the magnetic 
stirrer throughout the experiment. Samples were withdrawn from the 
outside of the dialysis bag at different predetermined time intervals 
(0.5, 1, 2, 3, 4, 8, 12, 24, and 48 h) and replaced with an equal volume 
of fresh release media. Absorbance of the samples was measured using 
UV-Visible Spectrophotometer (UV-1800, SHIMADZU, JAPAN) at 231.0 
nm and concentrations were calculated from the calibration curve of 
DTX in PBS containing 0.5% w/v SLS. The percentage of drug released 
was determined against the known amount of DTX in the sample 
initially taken into the dialysis bag.  
Stability study 
The stability of the lyophilized HA-DTX loaded nanoliposomes were 
evaluated at long term condition (5 °C±3 °C) and at accelerated 
condition (25 °C±2 °C, 60% RH±5% RH) for six months as per the 
guideline of the International Conference on Harmonization (ICH) 
Q1A(R2) [33]. Samples were withdrawn initially, after 1, 2, 3, and 6 
mo of storage and the particle size, zeta potential, drug loading and 
loading efficiency were determined as the criteria of stability study.  
In vitro cytotoxicity and cellular uptake studies 
Cell culture 
C6 glial cell line was grown in Ham’s F12 medium with 2 mmol L-
glutamine, 1.5 g/l sodium bicarbonate, and 10% FBS and antibiotics 
(10, 000 U/l penicillin and 10 mg/l streptomycin) and maintained in 
T-25 culture flask at 37 °C and 5% CO2 in a CO2-incubator 
(Eppendorf AG 22331, Hamburg, Germany).  
In vitro cytotoxicity study 
The cytotoxicity effect of L-NLs and marketed formulation (Daxotel) 
was investigated in C6 glial cells using a previously established MTT 
assay method [27, 34]. Briefly, 100 µl/well of C6 glial cell suspension 
at 2.5x104 cells/ml in incomplete media (media without FBS) was 
placed in a 96-well plate and kept for 24 h at 37 °C and 5% CO2 in a 
CO2-incubator (Eppendorf AG 22331, Hamburg, Germany). Different 
concentrations of DTX equivalent of L-NLs and marketed 
formulation were prepared in sterile water for injection and in 0.9% 
w/v Sodium Chloride injection, respectively. Then, the incomplete 
media was replaced with 100 μl of fresh in complete medium and 
the cells were treated with 100 µl/well of L-NLs and marketed 
formulation at final concentrations equivalent to 0.001, 0.01, 0.1, 1.0, 
5.0 and 10.0 μg/ml DTX. After incubation for 24 h, the incomplete 
media was discarded and 10 μl of MTT solution (5 mg/ml in cell-
based assay buffer) was added to each well and the plate was 
wrapped with aluminum foil and kept in the CO2 incubator for 4 h. 
After the incubation period, the supernatant MTT solution was 
discarded and 100 μl of solubilization solution taken from the assay 
kit was added to each well to dissolve the formed formazan 
precipitates produced by mitochondrial reductase enzyme of viable 
cells. Subsequently, the plate was loaded into a microplate reader 
(Spectrophotometer 1510, Thermo Scientific Multiskan GO, Finland) 
and shaken for 10 min, and the absorbance reading was taken at 570 
nm. The cytotoxicity effect was evaluated by calculating the 
percentage of cell viability relative to untreated cells (control). The 
percentage of cell viability was calculated using the following 
equation:  
% of cell viability =
Abs. of treated cells
Abs. of untreated cells
ₓ 100 
Where Abs. of treated cells is the absorbance of cells incubated with 
the L-NLs or marketed formulation at various DTX equivalent 
concentrations, and Abs. of untreated cells is the absorbance of cells 
incubated with media without FBS. 
Cellular uptake study by fluorescence microscopy 
C6 glial cells were seeded at 1 × 105 cells/well on coverslips in 
twelve-well culture plates in an incomplete medium (1 ml/well) for 
24 h at 37 °C and 5% CO2. After complete adhesion, L-NLs or 
marketed product solution (100 µl/well) each at a final 
concentration equivalent to 10 µg/ml DTX was then added to the 
cells and incubated for 24 h. After treatment with L-NLs or marketed 
product or without treatment, the cells were stained with 2 drops of 
5 μM Cell EventTM caspase-3/7 Green Reagent [35] for 30 min at 37 
°C in the dark. Stained cells were observed under inverted 
Fluorescence Microscope (CARL ZEISS Vert. A1, AXIO, Germany) 
through standard GFP (green fluorescent protein) filter with 
maximum excitation at 502 nm and maximum emission at 530 nm; 
and the fluorescence images (40x magnifications) of untreated 
(control) and treated cells were obtained.  
RESULTS AND DISCUSSION  
Synthesis and characterization of HA-DTX conjugate 
The general scheme of the synthesis of HA-DTX conjugate is 
represented in fig. 1. In the synthesis of the conjugate, a molecular 
weight (MW) of HA ~40-50 kDa was used because extremely lower 
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MW HA (<30 kDa) exhibited lower affinity to the CD44 receptor [36] 
while higher MW HA (>100 kDa) forms a gel or precipitates from 




Fig. 1: A general scheme of synthesis of Hyaluronic Acid-Docetaxel conjugate (HA-DTX) 
 
DTX was conjugated to the HA via an acid-cleavable ester linkage 
between 2´-OH group of DTX and -COOH group of HA. Similarly, it 
was reported that 2´-OH of paclitaxel (a drug having a similar 
structure to DTX) was bonded to -COOH of HA [28]. Prior to 
conjugation, -COOH group of HA was activated using EDC/NHS 
chemistry to make a more reactive towards -OH group of DTX. The 
formation of HA-DTX was characterized by UV-Visible 
Spectrophotometry, FT-IR, DSC, 1H NMR, and XRD. 
UV-Vis spectrophotometry 
Upon scanning from 400 nm to 200 nm, DTX and HA-DTX solutions 
showed absorption maxima (λmax) at 231.0 nm and 232.20 nm, 
respectively. The concentration of DTX in the HA-DTX conjugate was 
calculated from the standard calibration curve of DTX and obtained 
to be 474.33 µg/mg, i.e., 1 mg of HA-DTX contains 474.33 µg of DTX. 
The percent of DTX conjugation and the percent of the DTX loading 
amount was calculated using the formulas mentioned under 
‘methods’ section and the results are summarized in table 1. About 
half of the amount of DTX initially used in the reaction was 
conjugated to HA. 
Fourier-transform infrared (FT-IR) spectroscopy  
The FT-IR spectra of HA, DTX and HA-DTX were obtained and 
presented in fig. 2. The characteristic peaks (cm-1) 1708.0 (C=O 
stretching in ester bond), 1115.30 (C-O stretching in ester bond), 
1244.03 (O=C-O-C stretching in acetate) and 774.21 (aromatic C-H 
bending) of DTX spectrum showed small shifts to 1710.6, 1114.01, 
1243.48 and 772.32, respectively in the HA-DTX spectrum. Thus, the 
main characteristic peaks in DTX were also obtained in the spectrum 
of HA-DTX conjugate with slight shifts. In addition, a characteristic 
peak (1071.98 cm-1) of DTX spectrum, which corresponds to-C-O 
stretching of a secondary alcohol (-CH(R)-OH) and the peak 
(3235.22 cm-1) corresponding to the carboxylic acid group (–COOH) 
of HA spectrum were not observed in the spectrum of HA-DTX 
conjugate. Rather, a new peak (1739.50 cm-1), which corresponds to 
ester linkage, was observed in the spectrum of the HA-DTX 
conjugate. Thus, the disappearance of peaks corresponding to–OH 
group in DTX spectrum and–COOH group in HA spectrum and the 
appearance of new ester peak in the HA-DTX spectrum confirmed 
the formation of HA-DTX conjugate by an ester linkage. 
  
Table 1: Results showing the amount of HA and DTX used in feed for the synthesis of HA-DTX conjugate, the amount of the conjugate 
obtained, the percent of DTX conjugation and the DTX percent loading 
HA (mg) DTX (mg) HA-DTX obtained (mg) DA (mg) DC (%w/w) DL (%w/w) 
60.15 242.38  257.17±0.57 121.98±0.27  50.32±0.24  47.43±0.42 
Results are presented as mean±SD (n=3), HA: Hyaluronic acid, DTX: Docetaxel, DA: the amount of DTX in the HA-DTX conjugate, DC: percent of DTX 
conjugation (% w/w), DL: DTX percent loading (% w/w) 
 
Proton-nuclear magnetic resonance (1H NMR) spectroscopy 
In 1H NMR Spectroscopy, two different solvents were used to obtain 
characteristic proton peaks of DTX and HA [39]. 1H NMR spectra of 
DTX and HA-DTX in DMSO-d6 (fig. 3), and HA and HA-DTX in D2O (fig. 
4) were obtained. It was observed that when DMSO-d6 was used as a 
solvent, the characteristic peaks of DTX, such as multiplets in aromatic 
rings (7.299-7.964 ppm) appeared in the 1H NMR spectrum of HA-
DTX. In addition, when D2O was used as a solvent, a characteristic 
peak-CH3 of the acetamido moiety (-NHCOCH3) of HA was identified at 
1.850 ppm along with glucosidic H (10H) at 3.170-3.666 ppm. Hence, 
these results further confirmed the formation of HA-DTX conjugate. 
Seifu et al. 
Int J App Pharm, Vol 12, Issue 6, 2020, 88-99 
92 
 
Fig. 2: The FT-IR spectra of Hyaluronic acid (A), Docetaxel (B), and Hyaluronic acid-Docetaxel conjugate (C) 
 
 
Fig. 3: 1H NMR spectra of docetaxel (A) and Hyaluronic Acid-Docetaxel conjugate (B) in DMSO-d6 
Seifu et al. 
Int J App Pharm, Vol 12, Issue 6, 2020, 88-99 
93 
 
Fig. 4: 1H NMR spectra of Hyaluronic acid (C) and Hyaluronic Acid-Docetaxel conjugate (D) in D2O 
 
 
Fig. 5: DSC thermograms of docetaxel (A), Hyaluronic acid (B) and Hyaluronic Acid-Docetaxel (C) 
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Differential scanning calorimetry  
The DSC thermograms of DTX, HA and HA-DTX obtained are 
presented in fig. 5. DTX showed a characteristic endothermic peak 
at 164.54 °C, and HA showed an exothermic characteristic peak at 
239.36 °C. The DSC characteristic peaks of DTX and HA were not 
present separately in the thermogram of HA-DTX. This suggests 
that DTX was conjugated to HA, there by revealing a new entity, 
HA-DTX conjugate. This is supported by the report of Goodarzi et 
al. [40] that in the indirect conjugation of DTX to HA via adipic 
dihydrazide-functionalized Hyaluronic acid (HA-ADH), no 
characteristic DSC peaks of DTX and HA-ADH were obtained in the 
thermogram of the HA-DTX conjugate. The DSC results also 
support the FT-IR and 1H NMR results in confirming the formation 
of the HA-DTX conjugate. 
X-ray diffraction (XRD)  
Diffractograms showing the patterns of XRD of DTX and HA-DTX are 
presented in fig. 6. The diffractogram of free DTX showed 
characteristic peaks at 2θ values of 4.374, 7.150, 8.767, 10.328, 
11.037, 12.399, 13.940, 15.273, 16.532, 17.692, 18.437, 19.301, 
21.618, 23.213, 27.259, 28.130, and 29.322 degrees, which is in 
conformity with the previous reports [41, 42]. The main 
characteristic peaks appeared in DTX (4.374, 8.767, 10.328, 12.399, 
13.940, 15.273, 16.532, 17.692, and 18.437 degrees in fig. 6A) were 
also present in the diffractogram of HA-DTX (fig. 6B), showing the 
presence of the conjugate in crystalline/semi-crystalline form. The 
appearance of some new peaks such as 6.970, 13.412, and 23.960 
and the disappearance of existing peaks like 11.037, 19.301, 23.213, 
27.259 and 29.322 were also observed in the diffractogram of HA-
DTX, which might result from the formation of the conjugate. 
 
 
Fig. 6: X-Ray diffractograms of docetaxel (A) and Hyaluronic acid-docetaxel conjugate (B)  
 
Characterization of HA-DTX loaded nanoliposomes 
Percentage yield 
The yield of the dried nanoliposomes (L-NLs) was determined to know 
the amount of product obtained with respect to the total amount of raw 
materials used in the formulation and it was found to be 54.70%±2.30. 
Particle size, polydispersity index (PDI) and zeta potential  
The values of average particle size, polydispersity index and zeta 
potential of L-NLs were obtained by the Malvern particle size 
analyzer (ZEN3690, MALVERN, UK) and presented in table 2. 
  
Table 2: Physicochemical characteristics of HA-DTX loaded nanoliposomes 
Formulation code % DL % LE Particle size (nm) ZP (mV) PDI 
L-NLs 2.68±0.12  90.54±4.22  123.0±16.53 -44.4±6.79 0.246±0.01  
Results are presented as mean±SD (n=3), DL: Drug loading, LE: Loading efficiency, ZP: Zeta potential, PDI: Polydispersity index, L-NLs: HA-DTX 
loaded nanoliposomes  
 
The observed average particle size indicated that L-NLs can pass 
through and be retained in the tumor vasculature to get into the 
tumor cells via EPR effect. It has also been reported that 
nanocarriers with sizes in the range of 100 to 200 nm targeted brain 
cancer and other tumor tissues passively through the EPR effect [10, 
11, 43]. Also, the PDI value obtained showed the L-NLs were in 
narrow size distribution. Basically, PDI value of 0.1 to 0.25 shows 
that the liposomal vesicles are homogeneously distributed, having 
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good physical stability in the formulation [30]. The value of zeta 
potential can also predict the physical stability of the vesicles. A zeta 
potential value>+30 mV and/or<-30 mV indicates that the stability 
of liposomal vesicles is good [30, 44]. In this study, the value of the 
zeta potential of L-NLs was found to be -44.4 mV±6.79, suggesting 
that L-NLs had good colloidal stability. 
Percentage of drug loading and loading efficiency  
The percentage of drug loading (% DL) and loading efficiency (% LE) 
were presented in table 2. L-NLs exhibited good loading efficiency 
with 26.80±1.25 µg of drug per mg of the formulation. 
Surface morphology  
The surface morphology of L-NLs obtained by Scanning Electron 
Microscopy (SEM) was presented in fig. 7. The SEM image showed 
that L-NLs appeared to have a spherical shape with nano-
dimensions of size less than 200 nm. 
Fourier-transform infrared (FT-IR) spectroscopy  
The FT-IR spectra of soya lecithin, cholesterol, physical mixture (soya 
lecithin, cholesterol and HA-DTX), and the lyophilized nanoliposomal 
formulation (L-NLs) were obtained and presented in fig. 8 to 
investigate the interaction of the conjugate with the excipients. 
 
 
Fig. 7: The scanning electron microscopic image of L-NLs 
 
 
Fig. 8: The FT-IR spectra of soya lecithin (A), cholesterol (B), physical mixture (C) and HA-DTX loaded nanoliposomal formulation (L-NLs) (D) 
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When the spectrum of HA-DTX (fig. 2C above) was compared with that 
of the physical mixture of the formulation components (fig. 8C), it was 
observed that characteristic peaks (cm-1) of HA-DTX such as 1711.46 
(C=O stretching), 1111.67 (C-O stretching), 1165.38 (aliphatic ester O=C-
O-C stretching), 1241.86 (acetate O=C-O-C stretching), 774.37 and 
707.61 (monosubstituted aromatic C-H bending), 1369.78 (-(CH3)3 
bending), 1595.52 (aromatic ring C=C stretching), and 3369.94 (O-H 
stretching) appeared in the spectrum of the physical mixture with the 
slight shifting of the peaks indicating that there was no interaction of the 
conjugate with the excipients. However, when the spectrum of L-NLs 
was compared to those of the pure components of the formulation (i.e., 
soya lecithin, cholesterol and HA-DTX); no characteristic peaks (cm-1) of 
HA-DTX were obtained in the spectrum of L-NLs suggesting that HA-DTX 
was encapsulated by L-NLs completely and no free HA-DTX was 
available on the surface of L-NLs. This result is also supported by 
previous reports of various workers in this field [9, 45, 46]. 
In vitro drug release  
The in vitro drug release behavior of DTX from L-NLs was presented 
in fig. 9. The release profile demonstrated that the percent 
cumulative release of DTX from L-NLs was distinctly lower at pH 7.4 
(14.14%±1.23) compared to at pH 5.2 (57.72%±1.17) after 48 h. 
The higher drug release at pH 5.2 than that of at pH 7.4 revealed that 
the formulation could release the drug preferentially at the tumor 
cells as a target site. This low pH-selective release property may be 
because HA-DTX is linked by acid-cleavable ester bond, whereby it 
breaks down at acidic pH and enhances the release of DTX from the 
HA-DTX conjugate. However, the rate of drug release tended to be 
slow after 24 h, indicating sustained release of DTX from L-NLs. This 
implied L-NLs could maintain a steady concentration of DTX for a 
relatively long period, which would reduce the frequency of 
administration in clinical application. 
  
 
Fig. 9: Drug release profile of L-NLs in PBS at pH 5.2 and pH 7.4, each point represents mean±SD (n=3), abbreviation: L-NLs, HA-DTX 
loaded nanoliposomes 
 
In addition, the marketed formulation (Daxotel) was investigated for its 
release pattern in the physiological pH (in PBS, pH 7.4) at 37 °C, and it 
was found that more than 90% of DTX was released within 8 h and 
about 100% after 12 h, whereby L-NLs released only 4.18%±0.75 and 
8.42%±0.62 at 8 h and 12 h, respectively (fig. 10). The release pattern 
indicates that L-NLs are relatively stable at physiological pH 7.4, which 
stimulates the blood circulation and thus, there may not be a premature 
release of the drug before it reaches the tumor cells. It is also expected 
that such type of release in a selective pH medium would minimize 
exposure of healthy tissue to DTX during its circulation in the blood. 
  
 
Fig. 10: Drug release profile of L-NLs and marketed formulation (Daxotel) in PBS at pH 7.4, each point represents mean±SD (n=3), 
abbreviation: L-NLs, HA-DTX loaded nanoliposomes 
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Stability study 
The stability study results are presented in table 3. The results 
indicated no significant changes were observed in particle size, zeta 
potential, drug loading and loading efficiency of L-NLs stored at both 
long term (5 °C±3 °C) and accelerated (25 °C±2 °C, 60% RH±5% RH) 
storage conditions for six months. This is because the nanoliposomes 
were in a solid lyophilized form which has better stability than they 
would in liquid suspension form. Further, it was reported that 
anticancer drug-loaded nanoliposomes were found to be stable at 
higher storage conditions (40±2 °C/75±5% RH) for a period of three 
months [47]. The particle size of the L-NLs showed a slight increment 
after six months. This might be due to mild aggregates that have been 
formed among the nanoliposomes upon storage. 
  
Table 3: Stability study results of HA-DTX loaded nanoliposomes (L-NLs) at 5 °C±3 °C and at 25 °C±2 °C, 60% RH±5% RH 
Sampling time  % DL % LE Particle size (nm)  ZP (mV) 
Initial 2.68±0.12 90.54±4.22 123.0±16.53 -44.4±6.79 
Long term storage condition (5 °C±3 °C) 
1 mo 2.66±0.22 89.86±5.11 124.9±16.45 -42.4±7.03 
2 mo 2.64±0.19 89.19±4.85 118.3±18.66 -43.7±6.0 
3 mo 2.62±0.14 88.51±4.47 128.1±26.48 -46.6±5.97 
6 mo 2.61±0.18 88.49±4.70 142.7±5.98 -41.5±7.52 
Accelerated storage condition (25 °C±2 °C, 60% RH±5% RH) 
1 mo 2.65±0.13 89.65±4.89 126.4±14.27 -43.1±6.73 
2 mo 2.63±0.17 89.11±4.57 122.1±17.73 -43.8±7.81 
3 mo 2.62±0.15 88.32±4.47 131.1±23.24 -45.2±6.67 
6 mo 2.60±0.16 87.84±4.20 147.5±7.35 -42.9±5.91 
Results are presented as mean±SD (n=3), DL: Drug loading, LE: Loading efficiency, ZP: Zeta potential  
 
In vitro cytotoxicity study 
Past investigation on molecular characterization revealed that the 
changes in gene expression observed in rat C6 glial cell line were the 
most similar to those reported in human brain tumors [48]. Therefore, 
the cytotoxicity effect of L-NLs and marketed formulation at different 
concentrations equivalent to 0.001, 0.01, 0.1, 1.0, 5.0, and 10.0 μg/ml 
DTX was investigated using MTT assay method [29, 37] in rat C6 
glioma cells as a model in order to simulate human glioma. After 24 h 
of treatment, the result (fig. 11) showed that at lower concentrations 
(i.e., 0.001 to 1.0 µg/ml of DTX concentration), the cytotoxicity of L-
NLs was found to be lower (higher percentage of viable cells) than that 
of the marketed formulation. The reason for lower cytotoxicity of L-
NLs is that, at lower concentration, less amount of HA-DTX is released 
from the nanoliposomes and hence less amount of DTX becomes free 
from the HA-DTX conjugate by hydrolysis to exert its cytotoxicity 
effect. In case of the marketed formulation it contains free drug that 
can be released completely from the formulation. But, as the 
concentration increases to 5.0 and 10.0 µg/ml the cytotoxicity effect of 
L-NLs increased by 6.5% and 10.0%, respectively than that of the 
marketed formulation. The reason for this is that as concentration 
increases the amount of DTX that becomes free from L-NLs will 
increase regardless of the effect of efflux pumps. In the L-NLs, the 
conjugation of DTX to HA and the loading of HA-DTX into 
nanoliposomes prevent the drug from efflux pumps. To the contrary, 
the effect of efflux pumps governed by tumor cells [49, 50] increases in 
case of marketed formulation since it contains free drug that can easily 
be subjected to the entrapping of P-glycoprotein (P-gp) and other 
surface transporters whereby it is pumped out from the cells. This is 
supported by the finding of previous studies where it was reported 
that the HA-paclitaxel conjugate bypassed P-gp efflux mechanism in 
breast cancer cells (MDA–MB–231Br) and accumulated intracellularly 
to a greater degree than free paclitaxel [28]. This reveals that DTX 
conjugated to HA and loaded into nanoliposomes protects the drug 
from efflux pumps and retains the drug molecules within the tumor 
cells which may decrease the dose of DTX required in the treatment 
and hence minimizes the side effects related to dose. Further, the 
marketed formulation related side effects such as severe 
hypersensitivity reactions due to polysorbate 80 [51] used in the 
formulation can be avoided. Thus the cytotoxic effect of L-NLs on rat 
C6 glial cells was found to be increased when the concentration of DTX 
in the L-NLs increased due to non-interference of the efflux pump.  
 
 
Fig. 11: In vitro cytotoxicity of HA-DTX loaded nanoliposomes (L-NLs) (green bar) and marketed formulation (Daxotel) (red bar) against C6 
glial cells at different concentrations of DTX for 24 h of treatment (mean±SD; n = 3), Abbreviations: DTX, Docetaxel, HA, Hyaluronic acid 
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The other advantage of L-NLs over-marketed formulation is that 
DTX specifically targets cancer cells due to the binding of HA to 
CD44 receptors overexpressed in the cancer cells [52]. Also, L-NLs 
are preferentially localized in the tumor cells via EPR effect in which 
the leaky vasculature enhances entrance, and the poor drainage 
lymphatic system allows accumulation in the cells. Thus, L-NLs could 
be effective to target DTX to tumor cells, particularly to C6 glial cells 
by the simultaneous mechanism of passive targeting through EPR 
effect and active targeting via HA binding to CD44 receptor 
overexpressed in glioma cells, and hence it could be an effective 
therapy against glioma. 
Cellular uptake study by fluorescence microscopy  
Entrance of drug nanocarriers into cancer cells had a direct 
relation to their observed cytotoxic effect. Among others, 
activation of caspase 3 and caspase 7 is an essential event during 
apoptosis, making this an optimized way for the detection of 
apoptotic cells [35]. Apoptotic cells are characterized by 
morphological changes in both the nucleus and cytoplasm, such 
as nuclear condensation and cytoplasm, internucleosomal 
cleavage of DNA and formation of micronuclei, loss of plasma 
membrane asymmetry, and plasma membrane blebbing. These 
changes can be detected under a fluorescence microscope after 
staining the cells with Caspase-3/7 green reagent. Apoptotic 
cells with activated caspase-3/7 show green apoptotic nuclei; 
but the cells without activated caspase 3/7 exhibit no or minimal 
fluorescence signal [35]. 
In this study the untreated (control), market formulation and L-NLs 
(each at final concentration equivalent to 10.0 μg/ml DTX) treated 
C6 glial cells and stained with CellEvent™ Caspase-3/7 green reagent 
were observed under a fluorescence microscope and their 
fluorescence images were taken and presented in fig. 12. 
  
 
Fig. 12: Fluorescence images (40x magnifications) of untreated (control) (A), marketed formulation (Daxotel) treated (B) and L-NLs treated 
(C) (each at concentration equivalent to 10.0 μg/ml of DTX) C6 glial cells for 24 h using CellEvent™ Caspase-3/7 green reagent staining 
 
The images showed that minimal fluorescence was observed in 
control, indicating the absence of apoptotic cells. On the other hand, 
the fluorescence signal of L-NLs treated cells was more than that of 
marketed formulation treated cells, i.e., more apoptotic bodies were 
observed in L-NLs treated cells than that of the marketed formulation 
treated cells. This indicated that there was more cellular uptake of L-
NLs than that of marketed formulation and thus more apoptosis, 
which also supports the results of the cytotoxicity study obtained 
above. The most likely reasons for more cellular uptake of L-NLs than 
that of the marketed formulation are the avoidance of efflux pumps 
and the passive and active targeting of L-NLs to the tumor cells. 
CONCLUSION  
The developed HA-DTX loaded nanoliposomes showed a higher rate of 
DTX release in pH 5.2 than in pH 7.4 and controlled-release 
characteristics, and thus L-NLs could help to selectively accumulate DTX 
in the tumor cells without premature release and exhibit sustained 
therapeutic effect which, in turn, could help to minimize frequent 
administration of the drug in clinical use. Moreover, the in vitro 
cytotoxicity and microscopic fluorescence studies indicated that L-NLs 
exhibited better anticancer activity against C6 glial cells than the 
marketed formulation. Thus, HA-DTX loaded nanoliposomes were found 
to be more effective in targeting DTX to glioma cells than the marketed 
formulation and might be effective in the treatment of glioma. 
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